So what does this mean for the consumer?
The studies by the reviewers confirmed that amisulpride is an effective 'atypical' antipsychotic drug for patients with schizophrenia. Amisulpride also is just as effective as risperidone or olanzapine.
Overall, it was discovered to produce improved results, such as enhancement of overall mental state and wide-ranging negative symptoms. Amisulpride may be more tolerable and acceptable than the conventional antipsychotics, especially when it comes to the motor side effects (e.g. extrapyramidal side effects).
The individual who is being treated with an older conventional antipsychotic may want to switch to amisulpride if he or she has developed motor side effects or has negative symptoms of schizophrenia. For those individuals who are on risperidone or olanzapine, there is no solid evidence that amisulpride is any better or worse. More studies are required to determine what role amisulpride has on family responsibility, quality of life and expense of the drug in the long term.
http://www.cochrane.org/reviews/en/ab001357.html